COVID-19 疫苗接种：对恢复期血浆捐献者选择标准的影响。
COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
机构信息
Department of Transfusion Medicine, VCSG Government Institute of Medical Sciences and Research, Srinagar, Uttarakhand, India.
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant, Dehradun-248016, Uttarakhand, India.
出版信息
Transfus Clin Biol. 2021 Aug;28(3):308-309. doi: 10.1016/j.tracli.2021.05.002. Epub 2021 May 7.
Clinical management protocols for COVID-19 are evolving rapidly as more information about the epidemiology and pathophysiological changes in COVID-19 become available. However, no definite treatment of COVID-19 has been found till date. The COVID-19 convalescent plasma (CCP) therapy has emerged as an important investigational therapy in the management of COVID-19 patients. Additionally, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations for the blood centres on the CCP blood donor eligibility criteria after COVID-19 vaccination. More clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against those COVID-19 recovered individuals who are not vaccinated to understand the vaccine impact on the IgG titres of anti-SARS-CoV-2 antibodies.
随着关于 COVID-19 的流行病学和病理生理学变化的更多信息的出现，COVID-19 的临床管理方案正在迅速发展。然而，迄今为止还没有发现 COVID-19 的明确治疗方法。COVID-19 恢复期血浆（CCP）治疗已成为 COVID-19 患者管理中的一种重要研究性治疗方法。此外，监管机构，特别是印度输血理事会，必须在 COVID-19 接种疫苗后，就 CCP 献血者资格标准向血液中心发布一些临时建议。需要更多的临床试验来了解从接种过 COVID-19 疫苗的 COVID-19 康复者中采集的 CCP 的疗效，以及从未接种 COVID-19 疫苗的 COVID-19 康复者中采集的 CCP 的疗效，以了解疫苗对 SARS-CoV-2 抗体 IgG 滴度的影响。
Zotero 插件